

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus (HCoV)

Aleksandra Loczechin, Karin Seron, Alexandre Barras, Emerson Giovanelli, Sandrine Belouzard, Yen-Ting Chen, Nils Metzler-Nolte, Rabah Boukherroub, Jean Dubuisson, and Sabine Szunerits

ACS Appl. Mater. Interfaces, **Just Accepted Manuscript** • DOI: 10.1021/acsami.9b15032 • Publication Date (Web): 21 Oct 2019

Downloaded from pubs.acs.org on October 21, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus (HCoV)

Aleksandra Loczechin,^{1,2} Karin Séron,³ Alexandre Barras,¹ Emerson Giovanelli,¹ Sandrine Belouzard,³ Yen-Ting Chen,⁴ Nils Metzler-Nolte,² Rabah Boukherroub,¹ Jean Dubuisson,^{3} Sabine Szunerits^{1*}*

¹*Univ. Lille, CNRS, Centrale Lille, ISEN, Univ. Valenciennes, UMR 8520 - IEMN, F-59000 Lille, France*

²*Inorganic chemistry I, Bioinorganic Chemistry, Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Universitätsstr.150, 44801 Bochum, Germany*

³*University of Lille, CNRS, INSERM, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.*

⁴*Center of Molecular Spectroscopy and Simulation of Solvent-driven Processes (ZEMOS), Ruhr-University Bochum, 44801 Bochum, Germany*

Abstract

Therapeutic options for the highly pathogenic human coronavirus (HCoV) infections are urgently needed. Anti-coronavirus therapy is however challenging, as coronaviruses are biologically diverse and rapidly mutating. In this work, the antiviral activity of seven different carbon quantum dots (CQDs) for the treatment of human coronavirus HCoV-229E infections was investigated. The first generation of antiviral CQDs was derived by hydrothermal carbonization from ethylenediamine/citric acid as carbon precursors and post-modified with boronic acid ligands. These nanostructures showed a concentration dependent virus inactivation with an estimated EC_{50} of $52 \pm 8 \mu\text{g mL}^{-1}$. CQDs derived from 4-aminophenylboronic acid without any further modification resulted in the second-generation of anti-HCoV nanomaterials with an EC_{50} lowered to $5.2 \pm 0.7 \mu\text{g mL}^{-1}$. The underlying mechanism of action of these CQDs revealed to be inhibition of HCoV-229E entry that could

* To whom correspondence should be addressed: jean.dubuisson@ibl.cnrs.fr (Jean Dubuisson) and sabine.szunerits@univ-lille.fr (Sabine Szunerits)

1
2
3 be due to interaction of the functional groups of the CQDs with HCoV-229E entry receptors;
4 surprisingly, an equally large inhibition activity was observed at the viral replication step.
5
6
7

8
9 **Keywords:** Human coronavirus (HCoV); Carbon quantum dots (CQDs); Antiviral therapy;
10 Boronic acid; Multivalent interactions.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

The eradication of viral infections is an ongoing challenge in the medical field, not only due to the problem of spreading but also to virus' ability to escape therapy by genetic mutations. The lack of targeted antiviral therapeutics as well as the constant emergence of new viruses makes the search for antiviral agents a challenging and extremely needed research task.¹ As part of a global strategy to prevent epidemics, some severe emerging pathogens with great epidemic potential have been identified by the World Health Organization (WHO),² including next to Ebola virus disease, the highly pathogenic human coronavirus (HCoV) infections. While circulating HCoVs (HCoV-229E, HCoV-OC43, HCoV-NL63 and HKU1) cause relatively mild common cold-like respiratory tract infections, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle-East respiratory syndrome coronavirus (MERS-CoV) lead to pneumonia requiring hospitalization and intensive care.³ A total of 2266 laboratory-confirmed cases of MERS-CoV, including 804 associated deaths have been declared to WHO until now, with a high case-fatality rate (35%).⁴ As the virus is circulating in animals and humans, it may undergo further adaptation and cause a pandemic. Therefore, therapeutic options are urgently needed.

The current treatments for MERS-CoV are extrapolated from SARS-CoV and H1N1 influenza outbreaks.⁵⁻⁷ These include different combinations of small molecules with broad antiviral activity (e.g. ribavirin, corticosteroids, interferons (IFN)), and monoclonal and polyclonal antibody therapies.⁷⁻⁸ The membrane-anchored glycoprotein S has lately found to be essential for the interaction between the MERS-CoV and the host cell,⁸⁻⁹ and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit is nowadays considered as a viable antiviral strategy.

Recently, nanoscale materials have emerged as promising and efficient platforms to modulate the viral infection cycle.¹⁰ Given that attachment of viruses into host cells is favored by multivalent interactions, the multivalent character of nanostructures with their high surface to volume ratio, allowing the attachment of several ligands, makes them well adapted to interfere with viral attachment and blocking viral entry into cells.

In this work, we investigate the potential of functional carbon quantum dots (CQDs) as inhibitors of host cells infection by HCoV-229E coronavirus (**Figure 1**). CQDs with an average diameter below 10 nm and excellent water solubility are highly attractive for nanomedical applications due to a lack of visible signs of toxicity in animals.¹¹ They can be

synthesized quickly *via* several different inexpensive and simple methods, and their excellent optical properties offer *in vivo* tracking possibilities. It was recently demonstrated that CQDs are suitable scaffolds to interfere with the *entry* of viruses into cells.¹²⁻¹⁴ Boronic acid modified CQDs were able to inhibit for example HIV-1 entry by suppressing syncytium formation.¹³ Some of us have shown lately the potential of CQDs-functionalized with boronic acid and amine moieties to interfere with the *entry* of herpes simplex virus type 1.¹² Han and co-workers reported lately the potential of CQDs as viral inhibitors by activation of type I interferon responses.¹⁴

This unique study reveals that boronic acid functions can be responsible for the anti-HCoV activity. CQDs derived from citric acid/ethylenediamine and further conjugated by “click” chemistry with boronic acid functions display an effective 50% inhibition concentration $EC_{50}=52\pm 8 \mu\text{g mL}^{-1}$. Likewise, CQDs derived from 4-aminophenylboronic acid and phenylboronic acid without any further modification exhibit antiviral behavior with a decreased effective EC_{50} down to $5.2\pm 0.7 \mu\text{g mL}^{-1}$. The underlying mechanism of action of these CQDs revealed to be the CQDs interaction with the HCoV-229E S protein. Surprisingly, an equally large inhibition activity was observed at the viral replication step.




Figure 1: Influence of CQDs, prepared by hydrothermal carbonization, on binding of HCoV-229E virus to cells: (a) inhibition of protein S receptor interaction, (b) inhibition of viral RNA genome replication.

2. Results and Discussion

2.1. First-generation of CQDs inhibitors of host cell infections by HCoV-229E coronavirus: Boronic Acid Modified CQDs


2.1.1. Formation and Characterization

Carbon quantum dots formed from ethylenediamine/citric acid

Boronic acid derivatives have been proposed as low-toxicity agents for inhibiting the entry of various viruses.¹⁵⁻¹⁶ To test if such concepts can be extrapolated to human coronavirus HCoV-229E infections, boronic acid functional groups were chemically integrated onto CQDs-1 formed through hydrothermal carbonization of ethylenediamine/citric acid (**Figure 2A**). The approach consists of sealing the organic precursors within a Teflon-lined autoclave chamber and performing the formation of CQDs at elevated temperature under reduced pressure for 5 h. The pH value of the resulting CQDs suspensions was found to be 7.2 ± 0.2 ($n=5$). To remove larger precipitates, the as-obtained CQDs suspension was first centrifuged and then dialyzed against water for 24 h with a final yield of CQDs of 40%. CQDs-1 exhibit a spherical shape with an average diameter of 4.5 ± 0.2 nm (**Figure 2B**). XPS analysis (**Table 1**) indicates the presence of C, O and N. The C_{1s} high resolution XPS spectrum of CQDs-1 depicts three different carbon features: the graphitic C=C at 283.4 eV, 284.9 eV (C-H) and 286.4 eV (C-O, C-N) (**Figure 2C**). Analysis of the N_{1s} high resolution XPS shows the presence surface NH_2 groups (399.9 eV) (**Figure 2D**). The Raman spectrum of the CQD-1 (**Figure 2E**) display the characteristic G band at 1570 cm^{-1} related to in-plane vibration of sp^2 carbon, and the D band at 1350 cm^{-1} attributed to disorder and defects. The ratio of the intensity of these bands (I_D/I_G), used to express the extent of sp^2/sp^3 hybridization of carbon atoms,¹⁷ is found to be 0.93 ± 0.15 for all particles.¹⁸ XRD patterns indicate their crystalline nature (see SI, **Figure S1A**) with a broad diffraction peak centered at 25.5° corresponding to an interlayer spacing of 0.35 nm. This is larger than the spacing between (100) planes in bulk graphite (0.23 nm) due to the incorporation of functional groups along the edges of the CQDs.¹⁹ The UV/Vis of CQDs-1 (see SI, **Figure S1B**) reveals an absorption maximum at ≈ 242 nm attributed to $\pi-\pi^*$ transition of C=C and a band at 344 nm due to $n-\pi^*$ transition of C=O and C=N bonds.²⁰⁻²¹ The fluorescence quantum yield (QY) is 0.33 compared to that of quinine sulphate used as reference (QY, 0.54 in 0.12 M H_2SO_4) (see SI, **Figure S1C**). A wavelength-dependent fluorescence emission is observed (see SI, **Figure S1D**) where upon increasing the excitation wavelength, the emission gradually shifts to the red region with an increase in fluorescence intensity. The phenomenon of excitation-dependent emission is typical for such

nanostructures.⁵⁻⁷ The zeta potential and hydrodynamic size of the CQDs-1 are summarized in

Table 1.






Figure 2: (A) Schematic representation of the synthesis of CQDs 1-4; (B) TEM, magnified TEM, HR-TEM images and size distribution histograms of CQDs 1-4; (C) C_{1s} high resolution XPS spectrum of CQDs-1; (D) N_{1s} high resolution XPS spectrum of CQDs-1; (E) Raman spectrum of CQDs-1; (F) N_{1s} high resolution XPS spectrum of CQDs 2-4; (G) Raman spectrum of CQDs 2-4; (H) Photographs of CQDs 1-4 suspensions (1 mg mL⁻¹) after 1 month in water (W), PBS (0.01 M, P) and Dulbecco's Modified Eagle's medium (M).

Table 1. Physico-chemical characteristics of the CQDs.

CQDs	ζ (mV) ¹	Size (nm)	Hydrodynamic size (nm) ²	PDI	C _{1s} ³ (at. %)	O _{1s} (at. %)	N _{1s} (at. %)	B _{1s} (at. %)
CQDs-1	-9.9 ± 3.4	4.5 ± 0.2	11 ± 0.1	0.22 ± 0.11	72.6	12.5	14.9	-
CQDs-2	-7.9 ± 2.7	5.5 ± 0.3	12 ± 0.1	0.23 ± 0.11	68.8	13.9	17.3	-
CQDs-3	-15.9 ± 4.3	6.3 ± 0.4	12 ± 0.25	0.15 ± 0.10	67.9	7.3	20.3	4.5
CQDs-4	-15.9 ± 1.3	6.5 ± 0.4	11 ± 0.19	0.13 ± 0.10	68.5	13.6	17.9	-

¹ ζ : zeta potential, PDI Polydispersity index; ²the hydrodynamic size was recorded at 37°C, ³XPS was used to determine the atomic percentage of the elements respectively

Functionalization of CQDs-1

The formation of CQDs-3 is based on a two-step chemical process. In a first step, azido-functionalized CQDs-2 are prepared by coupling 2-azido acetic acid moieties to CQDs-1. The N_{1s} signal of CQDs-2 shows signals at 405.2 (-N=N⁺=N⁻) and 401.6 eV (N=N⁺=N⁻) in a 1:2 ratio, as theoretically expected (**Figure 2F**). The azide functions in CQDs-2 quantitatively react with alkyne functions as indicated by the absent of the azide band at 405.2 eV in the relevant spectra of CQDs-3 and CQDs-4 (**Figure 2F**). The band at 399.2 eV (-NH₂) is most likely resulting from partial hydrolysis of surface linked 2-azido acetic ester function. CQDs-4 were synthesized as control to check whether the triazole function acts as a passive linker or not.^{22 23} The morphologies of CQDs-3 and CQDs-4 are comparable to that of CQDs-1 with an average diameter of 6.25 ± 0.17 nm (**Figure 2B**) and diffraction peak centered at 25.3° for CQDs-3 (see SI, **Figure S1A**) and an average diameter of 6.50 ± 0.40 nm (**Figure 2B**) and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

diffraction peak centered at 25.4° for CQDs-4. The Raman spectra of the CQDs 2-4 (**Figure 2G**) remain indifferent to that of CQDs-1 displaying the characteristic G and D band with $I_D/I_G = 0.93 \pm 0.15$ for all particles.¹⁸ The colloidal stability of CQDs 1-4 in water, phosphate buffer (PBS, 10 mM) and Dulbecco's Modified Eagle's medium (M) was in addition examined. All the particles had good long-term colloidal stability as seen from the photographs in **Figure 2H**.

2.1.2. Cytotoxicity Assay

The cell toxicity of CQDs-1, CQDs-3 and CQDs-4 was established on Huh-7 cell lines after 8 h (time points corresponding to HCoV-229E infections) and 24 h incubation. The CQDs toxicity was evaluated using cell viability assessment by the resazurin assay, based on the conversion of non-fluorescent dye to a fluorescent molecule by mitochondrial and cytoplasmic enzymes. All CQDs are non-toxic to Huh-7 cells even at the highest concentration ($100 \mu\text{g mL}^{-1}$) investigated when incubated for 8 and 24 h (**Figure 3A**). Neither the presence of boronic acid nor triazole units had a negative effect on cell toxicity.

The uptake mechanism proved to be the same for all the nanostructures. Taking the example of CQDs-3 (which later proves to have antiviral activity), Huh-7 cells were fixed after 1 h incubation at 4°C and 37°C and then, nuclei were stained with Hoechst 33342, a fluorescent dye for labeling DNA in fluorescence microscopy (**Figure 3B**). The green fluorescence, which is attributed to the CQDs-3, is homogeneously distributed in the cytoplasm after 1 h when incubated at 37°C , which confirms the internalization of CQDs-3 inside the cells. The reduction of green fluorescence, observed in the cytoplasm after 1 h incubation at 4°C , suggests that the active internalization mechanism may be partially blocked and a small portion of CQDs was internalized by passive penetration.

The endocytosis of CQDs-3 was in addition quantitatively evaluated using flow cytometry by treating Huh-7 cells with $100 \mu\text{g mL}^{-1}$ of CQDs-3 for 1 h at 4°C and for 1, 3 and 6 h at 37°C (**Figure S2**). The excitation fluorescence of CQDs-3 at 488 nm allowed analysis of CQDs intracellularly. A progressive shift in the cell population towards higher fluorescence values was observed with a subsequent increase of time incubation due to the time-dependent cellular uptake likely through endocytosis. Lower fluorescence intensity was observed upon incubation at 4°C for 1 h, where active uptake process is blocked. The low percentage of green cells (0.8%) observed after 1 h at 4°C suggests that only a very low quantity of CQDs-

3 penetrates *via* passive uptake.




Figure 3. Characterization of post-functionalized CQDs: (A) Viability of Huh-7 cells treated with the different CQDs: Huh-7 cells were grown in 96-well plates (15×10^3 cells/well) with 100 μL of culture medium containing increasing concentration of CQDs for 8 h (left) and 24 h (right). The results, expressed as percentage of viability, are the mean value of two independent experiments with each treatment performed in triplicate. Negative control: without CQDs; (B) Fluorescence microscopy of Huh-7 cells treated with 100 $\mu\text{g mL}^{-1}$ of

CQDs-3 for 1 h at 4 °C (upper) and 37 °C (lower). The blue signal corresponds to the nuclei stained with Hoechst 33342, while the green signal is attributed to CQDs-3. Scale bars = 50 μm .

2.1.3. Antiviral assay of first-generation of antiviral CQDs

The antiviral activity of CQDs-1, CQDs-3 and CQDs-4 was evaluated on Huh-7 cells monolayers, infected with HCoV-229E-Luc (**Figure 4A**). Addition of CQDs-1 after 1 h infection and further incubation for 6 h at 37 °C shows no inhibition of infection. This contrasts to CQDs-3 where a concentration dependent virus inactivation is observed with an estimated $\text{EC}_{50}=52\pm 8 \mu\text{g mL}^{-1}$ (**Figure 4B**). Addition of mannose to CQDs-3 results in a complete loss of antiviral activity of the latter at low particle concentrations, with some antiviral activity above 50 $\mu\text{g mL}^{-1}$ CQDs. These data reveal two important findings. First, it highlights that boronic acid functions, where the mode of action is the selective and reversible formation of tetravalent complexes with *cis*-diols and thus glycan units,²⁴ are interacting with HCoV-229E. CQDs-3 are in this context speculated to be pseudolectins, targeting the S protein of HCoV-229E *via* a lectin-carbohydrate binding mechanism, similar to that of the oligomannose-specific lectin Griffithsin.²⁵ Thus the presence of mannose is blocking the antiviral activity is in favor of this mechanistic behavior. The presence of some antiviral activity of the mannose saturated CQDs-3 might be due to the presence of the triazole function on the particles' surface. Indeed, the control particles CQDs-4, bearing no boronic acid function but a triazole ring, display some antiviral activity, even though largely decreased when compared to CQDs-3.




Figure 4. Viral infection inhibition in the presence of CQDs: (A) Viral inhibition using CQDs at various concentrations. Huh-7 cells (1.5×10^4 cells/well) were inoculated with HCoV-229E-Luc for 1 h (in atmosphere with 5% CO_2 at 37 °C) in the presence or absence of

1
2
3 different CQDs in medium without FBS for 1 h. Afterwards, the inoculum was removed and
4 replaced with DMEM with FBS for 6 h. Cells were lysed, and luciferase activity quantified.
5 The results, expressed as percentage of infection normalized to the control without CQDs,
6 which is expressed as 100% infection. Data are means of two independent experiments with
7 each treatment performed in triplicate. (B) Determination of EC_{50} for CQDs-3 and CQDs-4,
8 and effect of viral inhibition using CQDs-3 after incubation with mannose (2:1) overnight at
9 $4^{\circ}C$.

18 **2.2. Second-generation of CQDs inhibitors of host cell infections by HCoV-229E** 19 **coronavirus**

20 **2.2.1. Formation and Characterization of CQDs 5-7**

21
22 With the aim to validate if boronic acid functions can be formed directly on CQDs,
23 hydrothermal carbonization of phenyl boronic acid and 4-aminophenylboronic acid were
24 performed resulting in CQDs-5 and CQDs-6 respectively (**Figure 5A**). As control,
25 hydrothermal carbonization of aniline and polyethylene glycol (PEG₆₀₀), both lacking boronic
26 acid functions, was conducted. Unfortunately, several attempts to prepare CQDs from aniline
27 as a starting material failed (see SI for experimental details).


28 The TEM images of CQDs 5-7 are seen in **Figure 5B**. CQDs-5 have an average diameter of
29 9.2 ± 0.3 nm, somehow larger than CQDs-6 with an average size distribution of 7.6 ± 0.2 nm
30 (**Table 2**). The particles formed from PEG (CQDs-7) display a spherical shape with an
31 average diameter of 8.0 ± 0.2 nm.





32 The XRD diffractograms (see SI, **Figure S3A**) display broad diffraction peaks centered at
33 21.3° for CQDs-5, 22.6° for CQDs-6, and 22.1° for CQDs-7, corresponding to an interlayer
34 spacing of 0.42 nm (CQDs-5), 0.40 nm (CQDs-6), and 0.39 nm (CQDs-7). The UV/Vis
35 absorption spectra of the CQDs are depicted in **Figure S3B**. The absorption shoulders at 250-
36 300 nm correspond to a typical absorption of an aromatic π system, in accordance with the
37 literature data.²⁶ The CQDs exhibit different fluorescence quantum yields (QY) of 0.03
38 (CQDs-5), 0.05 (CQDs-6), and 0.09 (CQDs-7) (**Figure S3C**). The wavelength-dependent
39 fluorescence emission properties of the CQDs are comparable (**Figure S3D**). The zeta
40 potential and hydrodynamic size of CQDs 5-7 are summarized in **Table 2**. Raman spectra of
41 the CQDs 5-7 (**Figure S3E**) remain indifferent to that of CQDs-1 displaying the characteristic
42 G and D band with $I_D/I_G = 0.93 \pm 0.15$ for all particles.

The chemical composition of the particles was thus further assessed using X-ray photoelectron spectroscopy and ^{11}B NMR. The XPS survey spectra of different CQDs (**Table 2**) indicate the presence of C_{1s} , O_{1s} , N_{1s} and B_{1s} in agreement with the chemical composition of the particles. Deconvolution of the C_{1s} XPS spectrum of CQDs-5 reveals bands located at 284.3 eV ($\text{C}=\text{C}$, sp^2); 285.1 eV ($\text{C}-\text{H}$, $\text{C}-\text{B}$) and a small contribution centred at 287.0 eV ($\text{C}=\text{O}$) (**Figure 5C**). The boron content is lower than that reported by Shen and Xi,²⁷ but comparable to that reported by Wang et al.²⁸ This indicates that some of the phenylboronic acid groups were carbonized under our experimental conditions. The low B content might also indicate doping rather than the presence of boronic acid function. CQDs-6 particles depict bands at 284.3 eV ($\text{C}=\text{C}$, sp^2), 285.2 eV ($\text{C}-\text{H}$, $\text{C}-\text{B}$), 287.3 eV ($\text{C}=\text{O}$) and a band at 290.3 eV due to $\text{O}-\text{C}=\text{O}$ functions. In the case of CQDs-7, the C_{1s} XPS spectrum comprises three different carbon features: the graphitic $\text{C}=\text{C}$ at 283.4 eV, 284.9 eV ($\text{C}-\text{H}$) and 286.4 eV ($\text{C}-\text{O}$, $\text{C}-\text{N}$). Analysis of the N_{1s} high resolution spectrum of CQDs-5 reveals the presence of surface $-\text{NH}_2$ groups (**Figure 5D**).

The FTIR spectra (**Figure 5E**) of CQDs 5-7 exhibit a distinct band at 3465 cm^{-1} attributed to the stretching vibration of $-\text{OH}$ groups and bands at around 2874 and 2924 cm^{-1} due to CH_2 stretching bands. The sharp band at 1618 cm^{-1} is assigned to graphitic $\text{C}=\text{C}$ and the $\text{C}-\text{H}$ deformation mode is seen at 1460 cm^{-1} . The $\text{C}=\text{O}$ band at $\sim 1780\text{--}1650\text{ cm}^{-1}$ is also visible in all cases. In the case of CQDs-6, the band at 1090 cm^{-1} might be due to $\text{C}-\text{B}$ stretching modes. This band is less defined in the case of CQDs-5, which might underline doping rather than the presence of boronic acid functions. The FTIR spectrum of CQDs-7 displays the $\text{C}-\text{O}-\text{C}$ bands of the PEG units at 1043 cm^{-1} .

CQDs 5-7 exhibited a negative zeta potential in water (pH 7.4) at room temperature and showed excellent long-term stability even in biological medium such as Dulbecco's Modified Eagle's medium (M) (**Figure 5F**).



(B)**(C)****(D)****(E)**





Figure 5: Chemical composition of the CQDs 5-7: (A) Schematic representation of the hydrothermal carbonization of different organic precursors for the synthesis of CQDs 5-7; (B) TEM, magnified TEM and size distribution histograms of CQDs 5-7; (C) C_{1s} high resolution XPS spectrum of CQDs 5-7; (D) N_{1s} high resolution XPS spectrum of CQDs-6; (E) FTIR spectra of CQDs 5-7; (F) Photographs of CQDs 5-7 suspensions (1 mg mL^{-1}) after 1 month in Dulbecco's Modified Eagle's medium (M).

Table 2. Physico-chemical characteristics of the CQDs 5-7.

CQDs	ζ (mV) ¹	Size (nm)	Hydrodynamic size (nm) ²	PDI	C_{1s} ³ (at. %)	O_{1s} (at. %)	N_{1s} (at. %)	B_{1s} (at. %)
CQDs-5	-20.0 ± 5.5	7.6 ± 0.2	13 ± 1.8	0.14 ± 0.09	77.4	21.7	-	0.9
CQDs-6	-41.2 ± 1.0	9.2 ± 0.3	12 ± 0.2	0.11 ± 0.06	69.4	21.5	7.4	1.7
CQDs-7	-39.2 ± 1.5	8.0 ± 0.2	13 ± 3.1	0.28 ± 0.34	60.8	39.2	-	-

¹ ζ : zeta potential, PDI Polydispersity index, ²the hydrodynamic size was recorded at 37°C ; ³XPS was used to determine the atomic percentage of the elements respectively

The cytotoxicity of CQDs 5-7 (**Figure 6**) is comparable to the CQDs discussed before (**Figure 3**), with CQDs-6 being slightly more toxic at concentrations $>25 \mu\text{g mL}^{-1}$ after 24 h incubation. This might be due to the presence of NH_2 groups on these particles. The uptake mechanism of these particles was comparable and is exemplified using CQDs-6 in **Figure S4**. Due to low intrinsic fluorescence CQDs-6 particles, they were labeled with fluorescein-NHS.



1
2
3 **Figure 6: Cell viability of CQDs 5-7:** Viability of Huh-7 cells grown in 96-well plates
4 (15×10³ cells/well) with 100 μL of culture medium containing increasing concentration of
5 CQDs5-7 labeled for 8 and 24 h. The results, expressed as percentage of viability, are the
6 mean value of two independent experiments with each treatment performed in triplicate.
7
8
9
10 Negative control: without CQDs.

11 12 13 **2.2.2. Antiviral assay of the second generation of CQDs 5-7**

14
15 Addition of CQDs-7 after 1 h infection and further incubation for 6 h at 37 °C showed no
16 inhibition of infection (**Figure 7A**), indicating that these particles are not interfering with
17 HCoV-229E-Luc entry or replication. CQDs-5 and CQDs-6 display a concentration
18 dependent virus inactivation. The dose-response curve (**Figures 7B**) reveals that the effective
19 concentration to achieve 50% inhibition (EC₅₀) against HCoV-229E-Luc infection is 5.2±0.7
20 μg mL⁻¹ for CQDs-6 and 11.6±1.1 μg mL⁻¹ for CQDs-5. Surprisingly, addition of mannose
21 did not result in a loss of the antiviral activity (**Figure 7C**), as observed previously for CQDs-
22 3.
23
24
25
26
27
28

29 Performing ¹¹B NMR analysis of CQDs-5 and CQDs-6 (**Figure 7D**) and comparing the
30 obtained spectra to those of the respective starting materials, 4-aminophenylboronic acid and
31 phenyl boronic acid (**Figure 7E**), reveals large differences in chemical composition. 4-
32 aminophenylboronic acid and phenyl boronic both exhibit a strong signal at around 29 ppm,
33 in accordance with literature data for -B(OH)₂ functions.²⁹⁻³⁰ The small signal at about 20 ppm
34 arises most likely from residual B(OR)₃ often used in boronic acid synthesis.³¹ The ¹¹B NMR
35 spectra of CQDs-5 and CQDs-6 display on the other hand peaks at 13 ppm (CQDs-5) and a
36 band at 10 ppm with a shoulder at 12 ppm for CQDs-6. This means that boron was
37 incorporated through doping rather than surface functionalization, during the hydrothermal
38 reaction. Indeed, one-pot solvothermal synthesis using aminophenylboronic acid precursor
39 was reported by Wang et al. to result in N and B co-doped CQDs.³² They indeed, reported the
40 presence of 0.7 at% B by XPS comparable to the amount obtained here (**Table 2**).
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





Figure 7. Viral infection inhibition in the presence of CQDs 5-7: (A) Viral inhibition using CQDs 5-7 at various concentrations. Huh-7 cells (1.5×10^4 cells/well) were inoculated with HCoV-229E-Luc for 1 h (in atmosphere with 5% CO_2 at 37 °C) in the presence or absence of different CQDs in medium without FBS for 1 h. Afterwards, the inoculum was removed and replaced with DMEM with FBS for 6 h. Cells were lysed, and luciferase activity quantified. The results, expressed as percentage of infection normalized to the control without CQDs, which is expressed as 100% infection. Data are means of two independent experiments with each treatment performed in triplicate; (B) Determination of EC_{50} for CQDs-5 and CQDs-6; (C) Viral inhibition using CQDs-5 and CQDS-6 after incubation with mannose (2:1) overnight at 4°C; (D) ^{11}B NMR spectra of CQDs-5 and CQDs-6 prepared by hydrothermal method from phenyl boronic acid (PBA) and 4-aminophenylboronic acid (4-APBA) precursors, respectively; (E) ^{11}B NMR spectra of 4-aminophenylboronic acid (4-APBA) and phenyl boronic acid (PBA) starting materials.

2.3. Mechanism of Action


We further investigated the mechanism of action of CQDs-3 and CQDs-6 on viral infection by performing a time-of-addition assay. CQDs (at $10 \mu\text{g mL}^{-1}$) were added at different time points during infection, as represented in **Figure 8A**. As expected, a strong inhibition of infection was observed when CQDs were added after 1 h inoculation. Moreover, the

inhibition activity of CQDs was stronger when the nanoparticles were added during the entry step, i.e. 30 min before and after inoculation and during inoculation. These results agree with our hypothesis of an interaction of CQDs with HCoV-229E S protein, or an interaction of CQDs with entry factors. Surprisingly, a strong inhibitory activity of CQDs was also observed when they were added after 5.5 h after the entry step, the replication step. The inhibition is not significantly different for the entry step compared to replication step. This suggests that, in addition to its major effect on HCoV-229E entry, CQDs can also affect the genomic replication of this virus. This could potentially be explained by an interaction between the CQDs and a cell surface protein leading to signal transduction affecting viral replication, or by an interaction with cytosolic proteins as CQDs are internalized.

To determine if CQDs are interacting directly with viral particles, HCoV-229E-Luc was incubated with CQDs at $10 \mu\text{g mL}^{-1}$ for 30 min at 37°C before inoculation. The inoculum was diluted 10 times, leading to a final concentration of CQDs of $1 \mu\text{g mL}^{-1}$, and infection assay was performed. In parallel, Huh-7 cells were inoculated with HCoV-229E-Luc in the presence of CQDs at 1 or $10 \mu\text{g mL}^{-1}$. The inoculum titers were kept constant in the different conditions. The results showed that the preincubation of the virus with CQDs at high concentration does not impair HCoV-229E infection meaning that CQDs are not interacting with the particles before infection (**Figure 8B**). Taken together, our results are in favor of an interaction of CQDs with cellular factors that may explain their antiviral effects at different steps of infection.



(A)






Figure 8. Time-of-addition assay of CQDs 3 and 6 during HCoV-229E infection. (A) CQDs at $10 \mu\text{g mL}^{-1}$ were added at different time points during infection of Huh-7 cells with HCoV-229E-Luc as shown below the graph. Cells were lysed, and luciferase activity quantified. Results are representative of 3 experiments performed in triplicate. Error bars represent SD of three independent values; (B) Virus HCoV-229E-Luc was preincubated with CQDs at $10 \mu\text{g mL}^{-1}$ for 30 min at 37°C . The mixture was diluted 10 times in culture medium leading to a final concentration of CQDs of $1 \mu\text{g mL}^{-1}$, and inoculated on Huh-7 cells for 1 h. In parallel, Huh-7 cells were inoculated with HCoV-229E-Luc in the presence of CQDs at 1 and $10 \mu\text{g mL}^{-1}$ for 1 h. Cells were lysed 7 h post-infection and luciferase activity quantified. Results are means of 3 experiments performed in triplicate. Error bars represent means of three independent values. Statistic evaluation (confidence interval of 95%), ns ($p > 0.99$); * ($p < 0.1$); ** ($p < 0.01$).

3. Conclusion

The viral infection cycle produces important biological and structural changes in the host cell, resulting in cell damage. The possibility to interfere with viral attachment to cells as well as viral replication to reduce viral infection and spreading is an appropriate antiviral approach. We presented here the antiviral performance of seven different CQDs with their main features summarized in **Table 3**. Three of these CQDs (CQDs 3, 5, 6) showed to interfering significantly with HCoV-229E-Luc infection in a concentration dependent manner, while CQDs-4 showed a very moderate antiviral activity. The estimated EC_{50} value decreased

considerable from CQDs-3, boronic acid modified quantum dots, derived from ethylenediamine/citric acid as carbon precursors ($EC_{50} = 52 \pm 8 \mu\text{g mL}^{-1}$) to $5.2 \pm 0.7 \mu\text{g mL}^{-1}$ in the case of CQDs-6. While the presence of boronic acid functions proved to be vital for covering CQDs-3 with antiviral activity, CQDs-5 and CQDs-6 did not carry a substantial amount of boronic acid functions, as revealed by ^{11}B NMR and validated by mannose addition experiments. These findings reveal the complex nature of identifying viral inhibitors for human coronaviruses such as HCoV-229E-Luc. Mechanistic studies suggest that the particles are acting at the early state of virus infection through the inhibition of entry that could be due to inhibition of protein S-receptor interaction with the host cell membrane. All different particles interfere in addition with the viral replication step, something less common. These results are extremely encouraging to replace currently used antiviral agents such as ribavirin and IFN known to have major side effects such as confusion, short-term memory loss, deficits in executive functions, as well as extrapyramidal effects. Further experimental confirmations are required if this approach can be extrapolated to other coronaviruses, notably to the clinically relevant MERS-CoV, to validate the potential of these nanostructures as alternative anti-MERS therapeutics and approaches to confront this severe and life-threatening disease. Also, how such particles work *in vivo* has to be shown in the future.

Table 3. Summary of the main features of CQDs 1-7

CQDs	Size (nm)	charge	functions	antiviral	EC ₅₀ / $\mu\text{g mL}^{-1}$
CQDs-1	4.5 ± 0.2	-9.9	NH ₂ , COO ⁻	-	
CQDs-2	5.5 ± 0.3	-7.9	N ₃	-	
CQDs-3	6.3 ± 0.4	-15.9	triazole, R-B(OH) ₂	++	52 ± 8
CQDs-4	6.5 ± 0.4	-15.9	triazole, OH	+	n.d.
CQDs-5	7.6 ± 0.2	-20.0	R-B(OH) ₂	+++	11.6 ± 1.1
CQDs-6	9.2 ± 0.3	-41.2	R-B(OH) ₂ , NH ₂	++++	5.2 ± 0.7
CQDs-7	8.0 ± 0.3	-39.2	PEG	-	

n.d. not determinable

4. Experimental

4.1. Materials

Citric acid, ethylenediamine, 4-aminophenylboronic acid, phenylboronic acid, poly (ethylene glycol) (PEG600, molecular weight 570-630), *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride, *N*-hydroxysuccinimide, propargyl alcohol, 4-pentynoic acid, copper sulphate pentahydrate, L-ascorbic acid, and sodium hydroxide were purchased from Sigma Aldrich. The dialysis membranes were supplied by Spectrum Laboratories.

4.2. Synthesis of functional carbon quantum dots (CQDs)

1
2
3 **CQDs-1** particles were synthesized following a method similar to that reported by Zhu *et al.*³³
4 (see supporting information **SI1** for more details) The details about the characterization
5 instruments can be found in the supporting information, **SI2**.
6
7

8 **CQDs-2**

9
10 Azide terminated CQDs-2 were obtained from CQDs-1 by the use of carbodiimide chemistry.
11 To a solution of 2-azidoacetic acid (1 mg mL⁻¹, 0.1X PBS) an equimolar amount of EDC·HCl
12 and NHS were added, and the solution was stirred for 20 min to activate the carboxyl group.
13 To this solution, CQDs-1 (1 mg mL⁻¹, 0.1X PBS) was added in a 1:2 volume ratio (v/v). The
14 reaction was carried out for 5 h at room temperature and the resulting solution was then
15 dialyzed against Milli-Q water using cellulose ester dialysis membrane for 24 h (Biotech CE
16 N°131093, molecular weight cut off 500-1000 Da) to remove unreacted material.
17
18
19
20
21
22

23 **CQDs-3**

24 CQDs-2 were further reacted with “clickable” phenyl boronic acid derivative 4-[(1-oxo-4-
25 pentyn-1-yl)amino]phenylboronic acid, synthesised as reported previously.³⁴ For this, CQDs-
26 2 (1 mg mL⁻¹, 5 mL). were mixed with 4-[(1-oxo-4-pentyn-1-yl) amino] phenylboronic acid (2
27 mM), copper sulphate pentahydrate (200 μM) and ascorbic acid (300 μM). The reaction
28 mixture was stirred for 24 h at room temperature. EDTA was added to the mixture prior to
29 dialysis (SpectraPor 1, pore size: 1000 Da) against Milli-Q water for 48 h.
30
31
32
33
34

35 **CQDs-4**

36 CQDs-2 were further reacted with commercially available propargyl alcohol. For this CQDs-2
37 (1 mg mL⁻¹, 5 mL) were mixed with propargyl alcohol (2 mM), copper sulphate pentahydrate
38 (200 μM) and ascorbic acid (300 μM). The reaction mixture was stirred for 24 h at room
39 temperature. EDTA was added to the mixture prior to dialysis (SpectraPor 1, pore size: 1000
40 Da) against Milli-Q water for 48 h.
41
42
43
44
45

46 **CQDs-5** and **CQDS-6** particles were prepared according to the protocol recently described by
47 us.¹²
48

49 **CQDs-7** particles were prepared in a similar manner as for CQDs-2 by dissolving PEG600
50 (200 mg) in water (20 mL) and adjusting the pH to 9.0 by adding NaOH (0.5 M). The solution
51 was degassed with nitrogen gas during 1 h to remove dissolved oxygen and heated in a
52 Teflon-lined autoclave chamber (125 mL – acid digestion vessel N°4748, Parr, France) for 72
53 h at 120 °C. After cooling to room temperature, the solution was dialyzed against water for 24
54 h with water being changed every 6 h (SpectraPor 1, pore size: 3500 Da).
55
56
57
58
59
60

4.3. Biological Assays

Cell and Toxicity Assay:

The Huh-7 hepatocarcinoma cell line was cultured and maintained in Dulbecco's Modified Eagle's medium (DMEM, Gibco®) supplemented with 10% fetal bovine serum (FBS, Gibco®) and 1% penicillin-streptomycin (Gibco®) in a humidified incubator at 37 °C and 5% CO₂. Cells were seeded at a density of 15×10³ cells/well in a 96-well plate and grown for 24 h before assay. The culture medium was replaced with a fresh medium that contains increasing concentrations of CQDs for 2 h and 8 h from 1 to 100 µg mL⁻¹. Then, the old medium was aspirated, and cells were washed with PBS. The cell viability was evaluated using resazurin cell viability assay. Briefly, 100 µL of the resazurin solution (11 µg mL⁻¹) in DMEM/10% FBS were added to each well and the plate was incubated for 4 h in the humidified incubator. The fluorescence emission of each well was measured at 593 nm (20-nm bandwidth) with an excitation at 554 nm (18-nm bandwidth) using a Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek Instruments SAS, France). Each condition was replicated three times and the mean fluorescence value of non-exposed cells was taken as 100% cellular viability.

Fluorescent Labeling of CQDs: Uptake Mechanism

To study the uptake mechanism of the particles into cells, CQDs were dissolved in PBS buffer (pH 7.4) at the concentration of 2 mg mL⁻¹. Fluorescein-NHS was dissolved in DMF (10 mg mL⁻¹). A solution of CQDs-5 was cooled down to 0°C and 10 µL of freshly prepared fluorescein-NHS solution was added. The reaction was stirred on ice for another 3 h. To remove the excess of the fluorescein dye, Sephadex G-25 PD-10 desalting column was used. Cells were seeded at a density of 15×10⁴ cells/well in a 24-well plate with sterile coverslips at the bottom and grown for 24 h before assay. The culture medium was replaced with a fresh medium that contained 100 µg mL⁻¹ of CQDs. After 1 h incubation at 4 °C and 37 °C, the Huh-7 cells were washed with PBS (three times), fixed with 4% paraformaldehyde for 10 min at room temperature and then stained with 10 µg mL⁻¹ Hoechst 33342 in PBS for 10 min at room temperature in the dark. After washing with PBS, the coverslips were mounted on glass slides and recorded using a Cytation™ 5 Cell Imaging Multi-Mode Reader (BioTek Instruments SAS, France) equipped with 40× objective (Plan Fluorite WD 2.7 NA 0.6). The fluorescence images were acquired with the same exposure using DAPI (377/447 nm) and GFP (469/525 nm) excitation/emission filter sets. All the images were processed using Gen5 Image+ software.

1
2
3 For cellular uptake, cells were seeded at a density of 15×10^4 cells/well in a 6-well plate and
4 grown for 48 h before assay. The culture medium was replaced with a fresh medium that
5 contained $100 \mu\text{g mL}^{-1}$ of CQDs. After 1 h incubation at 4°C and 1, 3, and 6 h incubation at
6 37°C , the Huh-7 cells were washed with PBS (three times) and collected by trypsinization.
7
8 The cells suspensions were resuspended in PBS/PFA 0.5% and analyzed through a flow
9 cytometer (BD LSR Fortessa) with FITC channel. The data were collected (10^4 cells per
10 sample) and analyzed using BD FACSDiva 8.0.1 software.
11
12
13
14
15
16

17 **Antiviral Assay: HCoV-229E-Luc**

18 We used a modified HCoV-229E containing a renilla luciferase reporter gene HCoV-229E-
19 Luc. The viral stocks were produced in Huh-7 cells. Huh-7 cells were infected with a pre-
20 stock of HCoV-229E-Luc in flasks. After 5 days, the supernatants of flasks were collected.
21 For infection assay, Huh-7 cells, 15,000/well seeded in 96-well plate, were inoculated with
22 HCoV-229E-Luc at a multiplicity of infection (MOI) of 1 during 1 h at 37°C in DMEM
23 without serum, then the inoculum was removed and cells were incubated in complete culture
24 medium for 6 h at 37°C . CQDs were added to cells during the 1 h of infection. Cells were
25 lysed in $20 \mu\text{L}$ of Renilla Lysis Buffer (Promega, Madison, USA) and luciferase activity
26 quantified using a Renilla Luciferase Assay System kit (Promega, Madison, USA) as
27 recommended by the manufacturer and a Tristar LB 941 luminometer (Berthold
28 Technologies, Bad Wildbad, Germany). To measure EC_{50} , dose-response experiment was
29 performed with CQDs added at different concentrations during inoculation step and post-
30 inoculation step. For time-of-addition assays, CQDs were added at different time points at
31 $10 \mu\text{g mL}^{-1}$. For all experiments, water was used as a control because CQDs are diluted in
32 water.
33
34
35
36
37
38
39
40
41
42
43
44

45 **Statistical Analysis**

46 The statistical test used is a Mann-Whitney nonparametric with a confidence interval of 95%.
47 The data were analyzed using GraphPad Prism (version 5.0b) by comparison between treated
48 and untreated groups (DMSO control). P values of 0.05 were considered to be significantly
49 different from the control.
50
51
52
53
54

55 **Acknowledgments**

56 Financial support from the Centre National de la Recherche Scientifique (CNRS), the
57 University of Lille, the Hauts-de-France region, the CPER "Photonics for Society", the
58 Agence Nationale de la Recherche (ANR) and the EU union through the Marie Skłodowska-
59
60

1
2
3 Curie action (H2020-MSCA-RISE-2015, PANG-690836) is gratefully acknowledged.
4 Research work is supported by the Belgian F.R.S. – FNRS project SELFPHON. We thank
5 Volker Thiel for providing us with HCoV-229E-Luc virus. We thank the Flow Core Facility –
6 BioImaging Center Lille (F-59000 Lille, France) for providing the technical environment to
7 perform flow cytometry analysis. Marc Bria is thanked for help in recording the ^{11}B NMR
8 spectra.
9
10
11
12
13
14

15 **Supporting Information:** Synthesis of functional cation quantum dots (CQDs-1, CQDs-5,
16 CQDS-6) as well as the synthesis of CQDs from aniline (**S1**); Description of methods used for
17 the characterization of CQDs (**S2**); Wavelength-dependent fluorescence emission properties
18 of the different CQDs (**Fig. S1**); Raman and some XPS high resolution (N_{1s} XPS of CQDs-2
19 and CQDs-3; C_{1s} of CQDs-7; N_{1s} of CQDs-7 (**Fig. S2**); Flow cytometry analysis of cellular
20 uptake of CQDs in Huh-7 cells treated with $100 \mu\text{g mL}^{-1}$ of CQDs-3 for 1 h at 4°C and 1, 3
21 and 6 h at 37°C (**Fig. S3**); Fluorescence microscopy of Huh-7 cells treated with $100 \mu\text{g mL}^{-1}$
22 of CQDs-5 labeled with fluorescein for 1 h at 4°C (upper) and 37°C (lower). The blue signal
23 corresponds to the nuclei stained (**Fig. S4**).
24
25
26
27
28
29
30
31
32
33
34
35

36 References

- 37
38 1. Nii-Trebi, N. I., Emerging and Neglected Infectious Diseases: Insights, Advances, and
39 Challenges. *BioMed Research International* **2017**, *2017*, 1-15.
40
41 2. <http://www.who.int/csr/research-and-development/meeting-report-prioritization.pdf>.
42 (accessed 16 September 2019)
43
44 3. Al Hajjar, S.; Ziad A. Memish, Z. A.; McIntosh, K., Middle East Respiratory
45 Syndrome Coronavirus (MERS-CoV): A Perpetual Challenge. *Ann Saudi Med.* **2013**, *33*, 427-
46 436.
47
48 4. [http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-november-2017.html)
49 [update-november-2017.html](http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-november-2017.html). (accessed 16 September 2019)
50
51 5. Mo, Y.; Fisher, D., A Review of Treatment Modalities Of Middle Respiratory
52 Syndroms. *J. Antimicrob. Chemother.* **2016**, *71*, 3340-3350.
53
54 6. Uyeki, T. M.; Erlandson, K. J.; Korch, G.; O'Hara, M.; Wathen, M.; Hu-Primmer, J.;
55 Hojvat, S.; Stemmy, E. J.; Donabedian, A., Development of Medical Countermeasures to
56 Middle East Respiratory Syndrome Coronavirus. *Emerging Infect. Disease* **2016**, *22*, 1-6.
57
58
59
60

- 1
2
3 7. Zumla, A.; Chan, J. F. W.; Azhar, E. I.; Hui, D. S. C.; Yuen, K.-Y., Coronavirus-Drug
4 Discovery and Therapeutic Options. *Nat. Rev.* **2016**, *15*, 327-347.
- 5
6 8. Du, L.; Yang, Y.; Zhou, Y.; Lu, L.; Li, F.; Jiang, S., MERS-Cov Spike Protein: A Key
7 Target for Antivirals. *Exp. Opin. Ther. Targets* **2017**, *21*, 131-143.
- 8
9 9. Lu, L.; Liu, Q.; Zhu, Y.; Chan, K.-H.; Qin, L.; Li, Y.; Wang, Q.; Chan, J. F. W.; Du,
10 L.; Yu, F.; Ma, C.; Ye, S.; Yuen, K.-Y.; Zhang, R.; Jiang, S., Structures-Based Discovery Of
11 Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor. *Nat. Commun.* **2014**, *5*,
12 3067, 1-15.
- 13
14 10. Szunerits, S.; Barras, A.; Khanal, M.; Pagneux, Q.; Boukherroub, R., Nanostructures
15 for the Inhibition of Viral Infections. *Molecules* **2015**, *20*, 14051-14081.
- 16
17 11. Lim, S. Y.; Shen, W.; Gao, Z., Carbon Quantum Dots And Their Applications. *Chem.*
18 *Soc. Rev.* **2015**, *44*, 362-381.
- 19
20 12. Barras, A.; Pagneux, Q.; Sane, F.; Wang, Q.; Boukherroub, R.; Hober, D.; Szunerits,
21 S., High Efficiency of Functional Carbon Nanodots as Entry Inhibitors of Herpes Simplex
22 Virus Type 1. *ACS Appl. Mater. Interfaces* **2016**, *8*, 9004-9013.
- 23
24 13. Fahmi, M. Z.; Sukmayani, W.; Qamariyah Khairunisa, S.; Witaningrum, A. M.;
25 Indriati, D. W.; Matondang, M. Q. Y.; Chang, J.-Y.; Kotaki, T.; Kameokaf, M., Design of
26 boronic acid-attributed carbon dots on inhibits HIV-1 entry. *RSC Adv.* **2016**, *6*, 92996-93002.
- 27
28 14. Du, T.; Liang, J.; Dong, N.; Liu, L.; Fang, L.; Xiao, S.; Ha, H., Carbon Dots As
29 Inhibitors Of Virus By Activation Of Type I Interferon Response. *Carbon* **2016**, *110*, 278-
30 285.
- 31
32 15. P. C. Trippier; Balzarini, J.; and C. McGuigan, A.; Phenylboronic-Acid-Based
33 Carbohydrate Binders As Antiviral Therapeutics: Bisphenylboronic Acids. *Chem.*
34 *Chemother.*, *21*, 129-142.
- 35
36 16. Khanal, M.; Barras, A.; Vauseilin, T.; Fénéant, L.; Boukherroub, R.; Siriwardena, A.;
37 Dubuisson, J.; Szunerits, S., Boronic Acid-Modified Lipid Nanocapsules: A Novel Platform
38 For The Highly Efficient Inhibition Of Hepatitis C Viral Entry. *Nanoscale* **2015**, *7*, 1392-
39 1402.
- 40
41 17. Gupta, V.; Chaudhary, N.; Srivastava, R.; Sharma, G. D.; R. Bhardwaj, R.; S. Chand,
42 S., Luminescent Graphene Quantum Dots for Organic Photovoltaic Devices. *J. Am. Chem.*
43 *Soc.*, **2011**, *133*, 9960-9963.
- 44
45 18. Yaoping, H.; Jing, Y.; Jiangwei, T.; Jun-Sheng, Y., How Do Nitrogen-Doped Carbon
46 Dots Generate From Molecular Precursors? An Investigation Of The Formation Mechanism
47 And A Solution-Based Large-Scale Synthesis. *J. Mater. Chem. B* **2015**, *3*, 5608-5614.
- 48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 19. Hu, C.; Liu, Y.; Yang, Y.; Cui, J.; Huang, Z.; Wang, Y.; Yang, L.; Wang, H.; Xiao,
4 Y.; Rong, J., One-Step Preparation Of Nitrogen-Doped Graphene Quantum Dots From
5 Oxidized Debris Of Graphene Oxide. *J. Mater. Chem. B* **2013**, *1*, 39-42.
6
7
8 20. Wang, S.; Cole, I. S.; Zhao, D.; Li, Q., The Dual Roles Of Functional Groups In The
9 Photoluminescence Of Graphene Quantum Dots. *Nanoscale* **2016**, *8* (14), 7449-7458.
10
11 21. Kim, T. H.; White, A. R.; Sirdarta, J. P.; Ji, W.; Cock, I. E.; St. John, J.; Boyd, S. E.;
12 Brown, C. L.; Li, Q., Yellow-Emitting Carbon Nanodots and Their Flexible and Transparent
13 Films for White LEDs. *ACS App. Mater. Interfaces* **2016**, *8*, 33102-33111.
14
15 22. Agalave, S. G.; Maujan, S. R.; Pore, V. S., Click Chemistry: 1,2,3-Triazoles as
16 Pharmacophores. *Chem. Asian J.* **2011**, *6*, 2696-2718.
17
18 23. Hilimire, T. A.; Chamberlain, J. M.; Anokhina, V.; Bennett, R. P.; O., S.; Myers, J. R.;
19 Ashton, J. M.; Stewart, R. A.; Featherston, A. L.; Gates, K.; Helms, E. D.; Smith, H. C.;
20 Dewhurst, S.; Miller, B. L., HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of
21 Replication-Competent and Multi-Drug-Resistant HIV in Human Cells. *ACS Chem Biol.*
22 **2017**, *12*, 1674-1682.
23
24 24. Yan, J.; Fang, H.; Wang, B., Boronolectins And Fluorescent Boronolectins: An
25 Examination Of The Detailed Chemistry Issues Important For The Design. *Med. Res. Rev.*
26 **2005**, *25*, 490-520.
27
28 25. O'Keefe, B. R.; Giomarelli, B.; Barnard, D. L.; Shenoy, S. R.; Chan, P. K. S.;
29 McMahan, J. B.; Palmer, K. E.; Barnett, B. W.; Meyerholz, D. K.; Wohlford-Lenane, C. L.;
30 McCray, P. B., Broad-Spectrum In Vitro Activity And In Vivo Efficacy Of The Antiviral
31 Protein Griffithsin Against Emerging Viruses Of The Family Coronaviridae. *J. Virol.* **2010**,
32 *84*, 2511-2521.
33
34 26. Li, H.; He, X.; Kang, Z.; Huang, H.; Liu, Y.; Liu, J.; Lian, S.; Tsang, C. H. A.; Yang,
35 X.; Lee, S.-T., Water-Soluble Fluorescent Carbon Quantum Dots and Photocatalyst Design.
36 *Angew. Chem. Int. Ed.* **2010**, *49*, 4430-4434.
37
38 27. Shen, P.; Xia, Y., Synthesis-Modification Integration: One-Step Fabrication of
39 Boronic Acid Functionalized Carbon Dots for Fluorescent Blood Sugar Sensing. *Anal. Chem.*
40 **2014**, *86*, 5323-5329.
41
42 28. Wang, Y.; Lu, L.; Peng, H.; Xu, J.; Wang, F.; Qi, R.; Xu, Z.; Zhang, W., Multi-Doped
43 Carbon Dots With Ratiometric Ph Sensing Properties For Monitoring Enzyme Catalytic
44 Reactions. *Chem. Commun.* **2016**, *52*, 9247-9250.
45
46 29. De Moor, J. E.; Van Der Kelen, P., Studies On Trivalent Boron Compounds II. Dipole
47 Moment Measurements. *J. Organomet. Chem.* **1967**, *9*, 23-29.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 30. Beachell, H. C.; Beistel, D. W., Nuclear Magnetic Resonance Spectra of
4 Phenylboronic Acids. *Inorg. Chem.* **1964**, *3*, 1028-1032.
- 5
6 31. Good, C. D.; Ritter, D. M., Alkenylboranes. II. Improved Preparative Methods and
7 New Observations on Methylvinylboranes. *J. Am. Chem. Soc.* **1962**, *84*, 1162-1166.
- 8
9 32. Wang, Y.; Lu, L.; Peng, H.; Xu, J.; Wang, F.; Qi, R.; Xu, Z.; Zhang, W., Multi-Doped
10 Carbon Dots With Ratiometric Ph Sensing Properties For Monitoring Enzyme Catalytic
11 Reactions. *Chem. Commun.* **2016**, *52*, 9247-9250.
- 12
13 33. Zhu, S.; Meng, Q.; Wang, L.; Zhang, J.; Song, Y.; Jin, H.; Zhang, K.; Sun, H.; Wang,
14 H.; Yang, B., Highly Photoluminescent Carbon Dots For Multicolor Patterning, Sensors, And
15 Bioimaging. *Angew. Chem. Int. Ed.* **2013**, *52*, 3953-3957.
- 16
17 34. Khanal, M.; Vausselin, T.; Barras, A.; Bande, O.; Turcheniuk, K.; Benazza, M.;
18 Zaitsev, V.; Teodorescu, C. M.; Boukherroub, R.; Siriwardena, A.; Dubuisson, J.; Szunerits,
19 S., Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics. *ACS Appl.*
20 *Mater. Interfaces* **2013**, *5*, 12488-12498.
- 21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TOC graphic

